WO2002016581A3 - Compositions and methods for the diagnosis and treatment of tumor - Google Patents

Compositions and methods for the diagnosis and treatment of tumor Download PDF

Info

Publication number
WO2002016581A3
WO2002016581A3 PCT/US2001/025464 US0125464W WO0216581A3 WO 2002016581 A3 WO2002016581 A3 WO 2002016581A3 US 0125464 W US0125464 W US 0125464W WO 0216581 A3 WO0216581 A3 WO 0216581A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
tumor
diagnosis
treatment
methods
Prior art date
Application number
PCT/US2001/025464
Other languages
French (fr)
Other versions
WO2002016581A2 (en
Inventor
Wei-Qiang Gao
Paul Polakis
Jianyong Shou
Victoria Smith
Robert Soriano
P Mickey Williams
Thomas D Wu
Zemin Zhang
Original Assignee
Genentech Inc
Wei-Qiang Gao
Paul Polakis
Jianyong Shou
Victoria Smith
Robert Soriano
P Mickey Williams
Thomas D Wu
Zemin Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/en
Priority claimed from PCT/US2001/006520 external-priority patent/WO2001068848A2/en
Priority claimed from US09/888,257 external-priority patent/US20030060612A1/en
Priority claimed from PCT/US2001/020118 external-priority patent/WO2002016429A2/en
Priority to EP01964006A priority Critical patent/EP1311662A2/en
Priority to CA002420176A priority patent/CA2420176A1/en
Application filed by Genentech Inc, Wei-Qiang Gao, Paul Polakis, Jianyong Shou, Victoria Smith, Robert Soriano, P Mickey Williams, Thomas D Wu, Zemin Zhang filed Critical Genentech Inc
Priority to JP2002522254A priority patent/JP2004520808A/en
Priority to MXPA03001644A priority patent/MXPA03001644A/en
Priority to KR10-2003-7002671A priority patent/KR20040014392A/en
Priority to AU2001284906A priority patent/AU2001284906A1/en
Publication of WO2002016581A2 publication Critical patent/WO2002016581A2/en
Publication of WO2002016581A3 publication Critical patent/WO2002016581A3/en
Priority to ZA2003/01204A priority patent/ZA200301204B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs

Abstract

The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
PCT/US2001/025464 2000-08-24 2001-08-14 Compositions and methods for the diagnosis and treatment of tumor WO2002016581A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2001284906A AU2001284906A1 (en) 2000-08-24 2001-08-14 Compositions and methods for the diagnosis and treatment of tumor
KR10-2003-7002671A KR20040014392A (en) 2000-08-24 2001-08-14 Compositions and Methods for the Diagnosis and Treatment of Tumor
MXPA03001644A MXPA03001644A (en) 2000-08-24 2001-08-14 Compositions and methods for the diagnosis and treatment of tumor.
JP2002522254A JP2004520808A (en) 2000-08-24 2001-08-14 Compositions and methods for tumor diagnosis and treatment
CA002420176A CA2420176A1 (en) 2000-08-24 2001-08-14 Compositions and methods for the diagnosis and treatment of tumor
EP01964006A EP1311662A2 (en) 2000-08-24 2001-08-14 Compositions and methods for the diagnosis and treatment of tumor
ZA2003/01204A ZA200301204B (en) 2000-08-24 2003-02-13 Compositions and methods for the diagnosis and treatment of tumor

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
USPCT/US00/23328 2000-08-24
PCT/US2000/023328 WO2001016318A2 (en) 1999-09-01 2000-08-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/006520 WO2001068848A2 (en) 2000-03-01 2001-02-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
USPCT/US01/06520 2001-02-28
PCT/US2001/020118 WO2002016429A2 (en) 2000-08-24 2001-06-22 Compositions and methods for the diagnosis and treatment of tumor
US09/888,257 US20030060612A1 (en) 1997-10-28 2001-06-22 Compositions and methods for the diagnosis and treatment of tumor
USPCT/US01/20118 2001-06-22
US09/888,257 2001-06-22

Publications (2)

Publication Number Publication Date
WO2002016581A2 WO2002016581A2 (en) 2002-02-28
WO2002016581A3 true WO2002016581A3 (en) 2003-01-16

Family

ID=25392866

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/025464 WO2002016581A2 (en) 2000-08-24 2001-08-14 Compositions and methods for the diagnosis and treatment of tumor

Country Status (4)

Country Link
EP (1) EP1311662A2 (en)
KR (1) KR20040014392A (en)
WO (1) WO2002016581A2 (en)
ZA (1) ZA200301204B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888477B2 (en) 1998-12-17 2011-02-15 Corixa Corporation Ovarian cancer-associated antibodies and kits
US6699664B1 (en) 1998-12-17 2004-03-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6858710B2 (en) 1998-12-17 2005-02-22 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6962980B2 (en) 1999-09-24 2005-11-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6468546B1 (en) 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
EP1621620A3 (en) * 1999-09-01 2006-05-10 Genetech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2003088808A2 (en) * 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
AU2003245615A1 (en) 2002-06-20 2004-01-06 The Regents Of The University Of California Compositions and methods for modulating lymphocyte activity
AU2003268494A1 (en) * 2002-09-11 2004-04-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003303144A1 (en) * 2002-10-18 2004-07-29 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004071530A2 (en) * 2003-02-05 2004-08-26 Genentech, Inc. Identification of cellular polypeptides differentially expressed by tumor cells
KR101520209B1 (en) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. Monomethylvaline compounds capable of conjugation to ligands
JP4993645B2 (en) 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド Antibody drug conjugates and methods
US8303952B2 (en) 2009-06-08 2012-11-06 Washington University Methods for inducing in vivo tolerance
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2019040780A1 (en) 2017-08-25 2019-02-28 Five Prime Therapeutics Inc. B7-h4 antibodies and methods of use thereof
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
BR112020017925A2 (en) 2018-03-02 2020-12-22 Five Prime Therapeutics, Inc. ANTIBODIES AGAINST B7-H4 AND METHODS OF USE OF THE SAME

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998042738A1 (en) * 1997-03-21 1998-10-01 Human Genome Sciences, Inc. 87 human secreted proteins
WO1999063088A2 (en) * 1998-06-02 1999-12-09 Genentech, Inc. Membrane-bound proteins and nucleic acids encoding the same
WO2000004140A1 (en) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 human secreted proteins
WO2000012708A2 (en) * 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998042738A1 (en) * 1997-03-21 1998-10-01 Human Genome Sciences, Inc. 87 human secreted proteins
WO1999063088A2 (en) * 1998-06-02 1999-12-09 Genentech, Inc. Membrane-bound proteins and nucleic acids encoding the same
WO2000004140A1 (en) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 human secreted proteins
WO2000012708A2 (en) * 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIU C ET AL: "Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 93, no. 16, 6 August 1996 (1996-08-06), Washington, DC, USA, pages 8618 - 8623, XP002213615 *

Also Published As

Publication number Publication date
ZA200301204B (en) 2005-01-26
KR20040014392A (en) 2004-02-14
EP1311662A2 (en) 2003-05-21
WO2002016581A2 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
WO2002016429A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2003024392A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2003000113A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2003088808A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2006110760A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2002016581A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2006029183A3 (en) Compositions and methods for the diagnosis and treatment of tumor
MXPA05005107A (en) Compositions and methods for the diagnosis and treatment of tumor.
WO2004112829A3 (en) Compositions and methods for the diagnosis and treatment of tumors of glial origin
EP2067472A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2007001851A3 (en) Compositions and methods for the diagnosis and treatment of tumor
AU6147401A (en) Compositions and methods for the treatment of cancer
WO2002016602A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2005049075A3 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
AU3227700A (en) Skin sanitizing compositions
WO2004024063A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2005063299A3 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
WO2004096124A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
AU2001283199A1 (en) Methods and compositions for the diagnosis and treatment of brown adipose cell disorders
MXPA03001644A (en) Compositions and methods for the diagnosis and treatment of tumor.
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
MXPA05008293A (en) Compositions and methods for the diagnosis and treatment of tumor.
WO2004019857A3 (en) Achaete-scute like-2 polypeptides and encoding nucleic acids and methods for the diagnosis and treatment of tumor
WO2003053334A3 (en) Compositions and methods for the diagnosis and treatment of tumor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001284906

Country of ref document: AU

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003/01204

Country of ref document: ZA

Ref document number: 200301204

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2420176

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/001644

Country of ref document: MX

Ref document number: 2002522254

Country of ref document: JP

Ref document number: 1020037002671

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001964006

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001964006

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020037002671

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2001964006

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020037002671

Country of ref document: KR